Research programme: cardiovascular disorders therapy - Merck/FoxHollow Technologies
Alternative Names: Atherosclerosis therapy research programme - Merck & Co/FoxHollow TechnologiesLatest Information Update: 19 Mar 2010
At a glance
- Originator FoxHollow Technologies; Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 05 Mar 2008 This programme is still in active development
- 27 Sep 2006 Merck & Co. expands the scope of its worldwide strategic research collaboration with FoxHollow Technologies
- 14 Sep 2005 Preclinical trials in Atherosclerosis in USA (unspecified route)